NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States
20 Novembre 2020 - 7:22PM
Business Wire
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN
: FR0011341205 – the ‘‘Company’’), a clinical-stage
nanomedicine company pioneering new approaches to the treatment of
cancer, today announced that it has filed a registration statement
on Form F-1 with the U.S. Securities and Exchange Commission (the
“SEC”) relating to a proposed initial public offering of its
American Depositary Shares (“ADSs”), representing ordinary
shares, in the United States (the “U.S. Offering”), and a
concurrent private placement of its ordinary shares in Europe
(including France) and other countries outside of the United States
(the “European Private Placement,” and together with the
U.S. Offering, the “Global Offering”). All securities to be
sold in the Global Offering will be offered by the Company. The
number of ordinary shares to be represented by each ADS, the number
of ADSs and ordinary shares to be offered and the price range for
the proposed Global Offering have not yet been determined. The
Company has applied to list its ADSs on the Nasdaq Global Market
under the ticker symbol “NBTX.” The Company’s ordinary shares are
listed on Euronext Paris under the symbol “NANO.”
Jefferies LLC is acting as global coordinator for the Global
Offering, and Evercore Group, L.L.C. and UBS Securities LLC are
also acting as joint book-running managers for the U.S. Offering.
Gilbert Dupont is acting as manager for the European Private
Placement.
The securities referred to in this press release will be offered
only by means of a prospectus. When available, copies of the
preliminary prospectus relating to and describing the terms of the
Global Offering may be obtained from Jefferies LLC, 520 Madison
Avenue New York, NY 10022, or by telephone at 877-547-6340 or
877-821-7388, or by email at Prospectus_Department@Jefferies.com;
or from Evercore Group L.L.C., Attention: Equity Capital Markets,
55 East 52nd Street, 35th Floor, New York, New York 10055, or by
telephone at 888-474-0200, or by email at
ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention:
Prospectus Department, 1285 Avenue of the Americas, New York, New
York 10019, or by telephone at 888-827-7275, or by email at
ol-prospectusrequest@ubs.com.
A registration statement relating to the securities referred to
herein has been filed with the SEC but has not yet become
effective. These securities may not be sold, nor may offers to buy
be accepted, prior to the time the registration statement becomes
effective. This press release does not constitute an offer to sell
or the solicitation of an offer to buy securities in any
jurisdiction, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of that jurisdiction. The registration statement
can be accessed by the public on the website of the SEC.
About NANOBIOTIX
Nanobiotix is a French, clinical-stage nanomedicine company
pioneering new approaches to significantly change patient outcomes
by bringing nanophysics to the heart of the cell. Nanobiotix’s
novel, proprietary lead technology, NBTXR3, is being evaluated in
locally-advanced head and neck squamous cell carcinoma (HNSCC) of
the oral cavity or oropharynx in elderly patients unable to receive
chemotherapy or cetuximab with limited therapeutic options.
Nanobiotix is also running an Immuno-Oncology development program.
The Company’s headquarters are in Paris, France, with a U.S.
affiliate in Cambridge, Massachusetts, and European affiliates in
France, Spain and Germany.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201120005663/en/
Nanobiotix Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com Investor
Relations Department Ricky Bhajun Senior Manager, Investor
Relations +33 (0)1 79 97 29 99 investors@nanobiotix.com Media
Relations US – Porter Novelli Scott Stachowiak +1(646)
300-3590 Scott.stachowiak@porternovelli.com France – Ulysse
Communication Pierre-Louis Germain + 33 (0)6 64 79 97 51
plgermain@ulysse-communication.com
Grafico Azioni Nanobiotix (EU:NANO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Nanobiotix (EU:NANO)
Storico
Da Apr 2023 a Apr 2024